Innogen Pharmaceutical
CompanyChina
Innogen Pharmaceutical develops one asset, in phase 2 (Efsubaglutide alfa in obesity). Mostly protein or enzyme acting on GLP1R; based in China.
- 1
- Asset
- Furthest stage
- Phase 2
- 0
- Trials
- 1
- Signal
Pipeline
1GLP-1 receptor agonist
Phase 2, Protein or enzyme, GLP1R, obesity, overweight
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms2
- Signals10
- Similar companies6
Papers
Efsubaglutide Alfa in Overweight or Obesity: Phase 2b ENLIGHT Study
ADA Scientific Sessions 2026 abstract, Jun 6, 2026
Efficacy and Safety of Efsubaglutide Alfa in Patients with Obesity or Overweight—A Phase 2 Study
ADA Scientific Sessions 2025 abstract, Jun 13, 2025